"The CHRONOS Study: Can the Sleep-deprivation Induced Antidepressive Effect in Patients With Major Depression be Sustained by Correction of Diurnal Rhythms, Long Term Light Treatment and Duloxetine Treatment?"
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Hamilton score during the 29 weeks trial
研究概览
简要总结
The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
详细描述
Protocol synopsis
Background:
The Psychiatric Research Unit at Frederiksborg General Hospital, with professor Per Bech as the driving force, has been working with sleep in relation to affective disorders for many years. During the last 4 years we have performed and been involved in several light therapy studies in depression, both in seasonal affective disorder (SAD), with light as an augmentation strategy in nonseasonal depression, in post-stroke depression and in Tourette's syndrome.
In relation to the dissemination of results from Klaus Martiny's Ph.D. thesis on bright light therapy as an augmenting strategy in major depression, our research unit has achieved close collaboration with some of the world's leading experts in chronotherapeutics: Professor Anna Wirz-Justice in Basel, Switzerland, Franscesco Benedetti in Milano, Italy, Michael Terman in New York, Mathias Berger in Freiburg, Germany and Joseph Wu at the University of California, Irvine. The basic idea of the present study comes from this group which over many years has performed and reported clinical studies in chronotherapeutics. We hope that our research unit will be able to conduct this study, as required, in a large patient sample and under the guidance of this group.
The study will fulfill the research unit's ambition to investigate antidepressive treatment algorithms with the propensity to lead to an earlier and sustained onset of action and a higher remission rate. Remission from depression does not only restore the patients' normal social functioning, but also reduces the risk of recurrence of depression. To attain this goal we regard the combination of new and powerful antidepressive drugs and non-pharmacological therapies most interesting and promising. This study has full support from the hospital administration who welcomes the active involvement of the nursing staff in the chronotherapeutic part.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of major depression according to DSM-IV
- •Patient with major depression as part of a bipolar disorder should be in adequate mood stabilizing therapy at entry to the study
- •Age of 18 or above
- •A score on the Hamilton Depression Scale, 17 items version of at least 18
排除标准
- •Primary psychotic disorder
- •Psychotic depression
- •Drug or alcohol abuse
- •Severe organic brain disease
- •Severe suicidal ideation (a score of 2 or above on the Hamilton Depression Scale, 17-items version)
- •Mental retardation
- •Pregnancy or lactation period
研究组 & 干预措施
A
Sleep deprivation in combination with light and duloxetine
干预措施: Sleep deprivation (Procedure)
A
Sleep deprivation in combination with light and duloxetine
干预措施: Light therapy (Procedure)
A
Sleep deprivation in combination with light and duloxetine
干预措施: Diurnal rhythms (Procedure)
A
Sleep deprivation in combination with light and duloxetine
干预措施: duloxetine (Drug)
B
Exercise and duloxetine
干预措施: Exercise (Behavioral)
B
Exercise and duloxetine
干预措施: duloxetine (Drug)
结局指标
主要结局
Hamilton score during the 29 weeks trial
时间窗: 1 week
次要结局
- Cortisol measurements(1 week)
- Depression self rating by the Preskorn scale(9 month)
